FDA says DesBio’s CHLA:10M, sold online for Chlamydia symptoms, is an unapproved new drug.
What happened
FDA reviewed DesBio’s website https://desbio.com/ in July 2026. It found CHLA:10M labeled as “Chlamydia 10M” and marketed for temporary relief of symptoms related to Chlamydia infection. FDA concluded the product is an unapproved new drug because no approved application is in effect.
What FDA found
The product is a drug because its label and webpage say it treats or relieves Chlamydia infection symptoms.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1); 21 CFR 201.128The product is a new drug because FDA does not generally recognize it as safe and effective for its labeled uses.
FD&C Act section 201(p), 21 U.S.C. 321(p)No FDA-approved application is in effect for CHLA:10M, so it is an unapproved new drug.
FD&C Act section 505(a), 21 U.S.C. 355(a)Introducing or delivering CHLA:10M into interstate commerce violates the FD&C Act.
FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)Labeling it “homeopathic” does not exempt it from drug approval requirements, and its Chlamydia trachomatis 10M ingredient is not listed in HPUS.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
What FDA wants
FDA asks DesBio to send a written response to FDAAdvisory@fda.hhs.gov within 15 business days of receipt. The response should include corrective steps, steps to prevent recurrence, related documentation, and reference number 735464.
Who should pay attention
- consumers who buy STI products online
- retailers and distributors of DesBio products
- homeopathic and supplement brands making disease-treatment claims
This is a summary. Read the original letter on fda.gov.